KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Operating Leases: 2022-2024

Historic Operating Leases for Recursion Pharmaceuticals (RXRX) over the last 3 years, with Dec 2024 value amounting to $67.2 million.

  • Recursion Pharmaceuticals' Operating Leases fell 44.13% to $50.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.0 million, marking a year-over-year decrease of 44.13%. This contributed to the annual value of $67.2 million for FY2024, which is 35.78% up from last year.
  • Recursion Pharmaceuticals' Operating Leases amounted to $67.2 million in FY2024, which was up 35.78% from $49.5 million recorded in FY2023.
  • Recursion Pharmaceuticals' Operating Leases' 5-year high stood at $67.2 million during FY2024, with a 5-year trough of $44.4 million in FY2022.
  • In the last 3 years, Recursion Pharmaceuticals' Operating Leases had a median value of $49.5 million in 2023 and averaged $53.7 million.
  • Data for Recursion Pharmaceuticals' Operating Leases shows a peak YoY soared of 35.78% (in 2024) over the last 5 years.
  • Yearly analysis of 3 years shows Recursion Pharmaceuticals' Operating Leases stood at $44.4 million in 2022, then climbed by 11.50% to $49.5 million in 2023, then spiked by 35.78% to $67.2 million in 2024.